A Clinical Pharmacologist's Response to Dr. Milton Packer's Perspective on the Results of the COMET Trial

Journal of Cardiac Failure

Volumn 9, Issue 6, 2003, Pages 454-457

  Shepherd, Alexander M M ^a,b  

^a Univ of Texas Health Science Center ^*

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; METOPROLOL TARTRATE;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL PHARMACOLOGY; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0346199335     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2003.08.005     Document Type: Editorial

References (36)

1. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial (comment). Lancet 2003;362:7-13.
2. Lundborg P, Steen B. Plasma levels and effect on heart rate and blood pressure of metoprolol after acute oral administration in 12 geriatric patients. Acta Med Scand 1976;200:397-402.
3. Bengtsson C, Johnsson G, Regardh CG. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther 1975;17:400-8.
4. Darmansjah I, Wong E, Setiawati A, Moeloek D, Irawati D, Siagian M, et al. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. J Clin Pharmacol 1990;30(Suppl):S39-45.
5. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.
6. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988;33(Suppl):S9-14.
7. Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990;30(Suppl):S17-27.
8. Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10(Suppl 11):S85-8.
9. von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987;33:511-3.
10. Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987;10(Suppl 11):S89-93.
11. McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988;36(Suppl 6):82-91.
12. Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 2000;40:844-53.
13. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
14. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998;32(Suppl 1):S22-30.
15. Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. Am J Hypertens 1998;11:9S-14S.
16. Feuerstein GZ, Ruffolo RR Jr. Carvedilol. A novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16(Suppl F):38-42.
17. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 2001;37:48-54.
18. Tantucci C, Bruni B, Dottorini ML, Peccini F, Motolese M, Lecaillon JB, et al. Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double-blind, placebo-controlled crossover study. Am Heart J 1990;120:467-72.
19. Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE. Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation. Clin Pharmacol Therap 1979;25:536-40.
20. Ellis ME, Hussain M, Webb AK, Barker NP, Fitzsimons TJ. The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients. Br J Clin Pharmacol 1984;17(Suppl 1):59S-64S.
21. Lofdahl CG, Svedmyr N. Cardioselectivity of atenolol and metoprolol. A study in asthmatic patients. Eur J Resp Dis 1981;62:396-404.
22. Oh VM, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J. Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol 1978;5:107-20.
23. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635-41.
24. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. (comment). Circulation 2000;101:1707-14.
25. Gong H, Sun H, Koch WJ, Rau T, Eschenhagen T, Ravens U, et al. Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation 2002;105:2497-503.
26. Kaumann A, Bartel S, Molenaar P, Sanders L, Burrell K, Vetter D, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999;99:65-72.
27. del Monte F, Kaumann AJ, Poole-Wilson PA, Wynne DG, Pepper J, Harding SE. Coexistence of functioning beta 1- and beta 2-adrenoceptors in single myocytes from human ventricle. Circulation 1993;88:854-63.
28. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 1991;325:1557-64.
29. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group (comment). JAMA 2000;283:1967-75.
30. Andersson B, Hamm C, Persson S, Wikstrom G, Sinagra G, Hjalmarson A, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. JACC 1994;23:1397-404.
31. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol (comment). Circulation 2000;102:546-51.
32. Johansson BW. Effect of beta blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction. Am J Cardiol 1986;57:34F-7F.
33. Hansen O, Johansson BW, Gullberg B. Clinical outcome of acute myocardial infarction in patients on treatment with beta-blockers or calcium antagonists. A study of 7,922 hospitalized first myocardial infarctions. Cardiology 1992;80:382-91.
34. Gullestad L, Dolva LO, Soyland E, Kjekshus J. Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise. Clin Physiol 1988;8:487-99.
35. Rolf Smith S, Kendall MJ, Worthington DJ, Holder R. Can the biochemical responses to a beta 2-adrenoceptor stimulant be used to assess the selectivity of beta-adrenoceptor blockers? Br J Clin Pharmacol 1983;16:557-60.
36. Dargie HJ. Beta blockers in heart failure (comment). Lancet 2003;362:2-3.